Form 4: Neuronetics 10% owner buys 500K shares

10% owner Jorey Chernett purchased 500,000 Neuronetics shares at a $1.35 average price, lifting his direct stake to 9,393,276 shares.

Summary

• On 03/27/2026, 10% owner Jorey Chernett purchased 500,000 shares of Neuronetics, Inc. (STIM).
• Weighted average purchase price was $1.35 per share, with trades executed between $1.28 and $1.41.
• Following the transaction, Chernett directly owns 9,393,276 common shares.
• Transaction coded "P" (open-market or private purchase); ownership reported as Direct (D).
• The reporting person undertook to provide detailed trade-by-trade pricing upon request.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal given the size of the insider purchase and increased alignment, though it lacks operational or financial detail.

Positives

• Significant insider purchase of 500,000 shares, a potential confidence signal.
• Average purchase price of $1.35 within a $1.28–$1.41 range, potentially setting a near-term reference level.
• Direct beneficial ownership rises to 9,393,276 shares, reinforcing alignment with shareholders.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

StockSavvy.ai notes that sizable insider purchases in small-cap medtech can bolster investor sentiment amid sector volatility and reimbursement dynamics, though trading reactions typically depend on forthcoming catalysts such as adoption trends and profitability milestones.

Comparison to Industry Standards

• Insider open-market purchases of this magnitude are notable among small-cap medtech peers; similar disclosures at firms like Nevro (NVRO) and iRhythm (IRTC) have at times preceded short-term momentum but have not consistently predicted underlying fundamentals.
• Compared with large-cap medtechs (e.g., Abbott Laboratories, Boston Scientific) where insider trades are a smaller fraction of float, a 500,000-share purchase in a micro/small-cap like Neuronetics is relatively more material to float and market sentiment.
• Unlike structured financings seen at some peers (e.g., PIPEs or 13D-related group accumulations), this event reflects personal open-market buying rather than company-led capital raising, avoiding dilution risk.

Stakeholder Impact

• Shareholders: Insider buying may support sentiment and perceived alignment.
• Employees and customers: No direct operational changes indicated.
• Suppliers and creditors: No impact disclosed.

Next Steps

• No future actions disclosed.

Key Dates

Recommendation

The sizable insider purchase is a constructive signal, but without accompanying operational, financial, or strategic updates, maintaining a neutral stance is prudent pending additional catalysts or results.

Keywords

insider buying, Neuronetics, STIM, Form 4, Jorey Chernett, 10% owner, common stock, open market purchase, weighted average price, medical device, transcranial magnetic stimulation, mental health